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Introduction 
Choroid plexus tumors are rare tumors 
of the brain. They account for 0.3-0.6% of 
all brain tumors.1 Fifty percent of these 
tumors occur in the lateral ventricle, 40% in 
the fourth ventricle, 5% in the third 
ventricle, and 5% are multifocal.1,2 Grading 
of choroid plexus tumors is based on World 
Health Organization (WHO) classification.3 
Choroid plexus papilloma is grade I, 
atypical choroid plexus papilloma is grade 
II, and choroid plexus carcinoma is grade 
III.  
For both choroid plexus papilloma and 
choroid plexus carcinoma, age at 
presentation correlates with the location of 
the tumor.4 Lateral ventricle tumors are 
more common in children less than 10 years 
old, while fourth ventricle tumors are 
distributed evenly up to 50 years of age. 
Choroid plexus papilloma is well-
differentiated and usually has a benign 
course and carries a good prognosis after 
complete resection. Occasionally, there can 
be a malignant transformation to a choroid 
plexus carcinoma at recurrence. These are 
aggressive tumors characterized by brisk 
mitotic activity, increased cellularity, 
nuclear pleomorphism, focal necrosis, loss 
of papillary architecture, and invasion of 
neural tissue. Presenting symptoms often are 
related to cerebrospinal fluid obstruction, 
such as headache, diplopia, and ataxia.  
We present a rare case of atypical 
choroid plexus papilloma in an adult who 
was treated with single agent chemotherapy. 
Case Report 
A 52-year-old woman was referred for 
chemotherapy of recurrent atypical choroid 
plexus papilloma. She initially was 
diagnosed with choroid plexus papilloma 
and underwent resection. The tumor 
recurred on multiple occasions and the 
patient was treated with surgery (three 
resections) and stereotactic radiosurgery. 
The last surgery was thirteen years post 
diagnosis. The pathology result was positive 
for atypical choroid plexus papilloma 
(Figure 1). Her last MRI (Figure 2) showed 
the recurrence of the tumor in the pons area. 
Due to the location of the tumor, she was not 
recommended for surgery and referred to 
medical oncology for systemic chemo-
therapy. At relapse, the patient complained 
of headaches and neuropathic pain in the 
right neck when rotated. She also had right 
facial nerve palsy with numbness secondary 
to previous surgeries. 
 
 
Figure 1. Atypical Choroid Plexus 
Papilloma shows nuclear pleomorphism 
(with increased mitotic activity). 
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Figure 2. T1 contrast-enhanced image shows 
a right cerebellopontine angle papilloma 
(red arrow). 
 
Bevacizumab was started as a single 
agent therapy, as per recommended dosing 
and schedule used to treat other brain tumors 
(e.g., glioblastoma multiforme). On a 28 day 
cycle, bevacizumab was administered on 
day one and day fifteen. The only 
appreciable adverse event the patient 
developed was grade 2 hypertension 
managed with oral anti-hypertensives. MRI 
was repeated after completion of two cycles 
of bevacizumab and showed stable disease. 
During treatment, the patient had surgery 
for her right facial nerve palsy. 
Bevacizumab was held after four and one-
half cycles (almost two months before 
surgery) and was restarted 45 days after 
surgery. MRI after surgery showed stable 
disease. After eight cycles of bevacizumab, 
a follow-up MRI showed a minimally 
decreased enhancing lesion involving the 
right cerebellopontine angle cistern near the 
inferior pons. The patient was maintained on 
single agent bevacizumab without evidence 
of progression. 
Discussion 
Choroid plexus is the neuroepithelial 
tissue that produces cerebrospinal fluid. 
Choroid plexus tumors are intraventricular, 
papillary neoplasms derived from choroid 
plexus epithelium and are supported by well 
vascularized connective tissue.5,6 In 2007, an 
intermediate entity called atypical choroid 
plexus papilloma was introduced in the 
WHO classification of tumors of the central 
nervous system.7 
Atypical choroid plexus papilloma is 
distinguished from choroid plexus papilloma 
by increased mitotic activity of two or more 
mitoses per ten randomly selected high 
power fields.8 Up to two of the following 
features may be present: increased 
cellularity, nuclear pleomorphism, blurring 
papillary pattern (solid growth), and areas of 
necrosis.8 Clinical features and treatment 
outcomes of atypical choroid plexus 
papilloma have not been well established in 
the literature. Bevacizumab acts by binding 
and inhibiting vascular endothelial growth 
factor and decreasing microvascular growth 
and metastatic progression.9  
Bevacizumab’s mechanism of action and 
the vascular nature of this tumor need 
further evaluation. Given the rarity of this 
cancer, this case report illustrated one 
possible therapeutic strategy if resection 
and/or radiation are no longer options. 
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